Notably, one of these compounds, NGR-TNF (consisting of CNGRCG peptide fused to tumor necrosis factor-alpha), has been tested in patients with relapsing/refractory primary central nervous system lymphoma (PCNSL), with evidence of antitumor efficacy and good tolerability [20, 22, 23]. Here, TNF is linked to primary central nervous system lymphoma.